Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly/Isis Affinitak development dropped

Executive Summary

Isis "will not invest further in the development of Affinitak," firm says following failure of second pivotal non-small cell lung cancer trial conducted by partner Lilly. Study investigated the antisense inhibitor in combination with Lilly's Gemzar (gemcitabine) and cisplatin; trial results were to determine fate of drug after failure of first Phase III trial in combination with paclitaxel and carboplatin (1"The Pink Sheet" March 24, 2003, p. 29)...

You may also be interested in...



Lilly/Isis Affinitak Pivotal Trial Fails: Future Rests On Second Phase III Study

Lilly will await results from a second Phase III Affinitak study before making a final decision regarding its future role in developing Isis' antisense agent for non-small cell lung cancer

Qiagen’s Ambitions: Standing Alone & Strengthening Infectious Disease Portfolio

Antoine Marchal, Franchise Head PCR Core Labs - BA Molecular Diagnostics at Qiagen outlines how NeuModx will strengthen its position in the infectious disease space.

 

Bayer's Job Cuts And Flat 2021 Sales Outlook Disappoint

Licensing agreements and bolt-on acquisitions to strengthen its R&D pipeline are still in Bayer’s sights as the COVID-19 pandemic and currency devaluations have led to the need for job cuts and substantial cost savings at the big pharma company.

Topics

UsernamePublicRestriction

Register

MT142539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel